[go: up one dir, main page]

ZA200705898B - Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors - Google Patents

Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors

Info

Publication number
ZA200705898B
ZA200705898B ZA200705898A ZA200705898A ZA200705898B ZA 200705898 B ZA200705898 B ZA 200705898B ZA 200705898 A ZA200705898 A ZA 200705898A ZA 200705898 A ZA200705898 A ZA 200705898A ZA 200705898 B ZA200705898 B ZA 200705898B
Authority
ZA
South Africa
Prior art keywords
inhibitors
glycine transporter
phenyl methanone
methanone derivatives
derivatives
Prior art date
Application number
ZA200705898A
Other languages
English (en)
Inventor
Jolidon Synese
Norcross Roger David
Narquizian Robert
Pinard Emmanuel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200705898B publication Critical patent/ZA200705898B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
ZA200705898A 2005-01-26 2007-07-18 Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors ZA200705898B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05100473 2005-01-26

Publications (1)

Publication Number Publication Date
ZA200705898B true ZA200705898B (en) 2009-07-29

Family

ID=36121826

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705898A ZA200705898B (en) 2005-01-26 2007-07-18 Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors

Country Status (19)

Country Link
US (1) US7442710B2 (fr)
EP (1) EP1844045B1 (fr)
JP (1) JP4829900B2 (fr)
KR (1) KR100915472B1 (fr)
CN (1) CN101146808B (fr)
AR (1) AR052662A1 (fr)
AT (1) ATE447572T1 (fr)
AU (1) AU2006208547B2 (fr)
BR (1) BRPI0607241A2 (fr)
CA (1) CA2595605A1 (fr)
DE (1) DE602006010175D1 (fr)
ES (1) ES2332529T3 (fr)
IL (1) IL184561A (fr)
MX (1) MX2007008918A (fr)
NO (1) NO20073717L (fr)
RU (1) RU2007126951A (fr)
TW (1) TW200637859A (fr)
WO (1) WO2006079467A1 (fr)
ZA (1) ZA200705898B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
US9045459B2 (en) * 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2016029454A1 (fr) * 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. Dérivés de tétrahydronaphtyridine comme modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
CN111393366B (zh) * 2020-06-05 2020-09-01 北京华氏开元医药科技有限公司 四氢异喹啉类衍生物、制备方法、药物组合物及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5017800B1 (fr) * 1967-08-02 1975-06-24
JPS5017998B1 (fr) * 1970-06-02 1975-06-25
JPS5017999B1 (fr) * 1970-06-02 1975-06-25
DE2423847A1 (de) * 1973-05-28 1975-01-02 Ciba Geigy Ag Neue sulfamoylbenzoesaeureamide
DE2611705A1 (de) * 1976-03-18 1977-09-22 Josef Dipl Chem Dr Rer N Klosa N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel
IT1176613B (it) 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
IL138228A0 (en) 1998-03-06 2001-10-31 Janssen Pharmaceutica Nv Glycine transport inhibitors
HUP0101281A3 (en) 1998-03-06 2001-11-28 Janssen Pharmaceutica Nv Diphenyl-piperidine butanamides as glycine transport inhibitors, process for producing them, use of them for producing medicaments and the pharmaceutical compositions containing them
AP2002002603A0 (en) * 2000-01-24 2002-09-30 Warner Lambert Co 3-aminoquinazolin-2,4-dione antibacterial agents.
CA2406652A1 (fr) 2000-04-20 2001-11-01 Nps Allelix Corp. Aminopiperidines
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
AU2001290786A1 (en) * 2000-09-14 2002-03-26 Gliatech, Inc. Nitrogen-containing compounds and their use as glycine transport inhibitors
AU2002344951A1 (en) 2001-07-02 2003-01-21 Boehringer Ingelheim International Gmbh Substituted piperazine and diazepanes as histamine h3 receptor agonists
WO2003035602A1 (fr) 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
MXPA05003660A (es) * 2002-10-21 2005-06-08 Warner Lambert Co Derivados de quinolina como antagonistas de crth2.
AU2003274053A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
EP1489071A1 (fr) * 2003-06-18 2004-12-22 4Sc Ag Dérivés de 3,4-dihydro-1H-isoquinoline N-substitués utilisés comme modulateurs de canaux de potassium
US20050070570A1 (en) * 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
GB0314479D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Compounds
NZ544820A (en) * 2003-08-11 2009-02-28 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
KR100774621B1 (ko) * 2003-09-09 2007-11-14 에프. 호프만-라 로슈 아게 정신병 치료용의 글라이신 섭취 억제제로서의1-벤조일-피페라진 유도체
CN1874777B (zh) * 2003-09-09 2012-07-04 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂用于治疗精神病的1-(2-氨基-苯甲酰基)-哌嗪衍生物
GB0329362D0 (en) 2003-12-18 2004-01-21 Glaxo Group Ltd Compounds
EP1761497B1 (fr) * 2004-01-09 2008-09-03 Corcept Therapeutics, Inc. Composes d'azadecaline utilises en tant que modulateurs du recepteur glucocorticoide
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
EP1745018A1 (fr) 2004-04-29 2007-01-24 Merck & Co., Inc. Inhibiteurs de transporteur de glycine à base d'azétidine
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof

Also Published As

Publication number Publication date
US20060167023A1 (en) 2006-07-27
DE602006010175D1 (de) 2009-12-17
MX2007008918A (es) 2007-08-21
CA2595605A1 (fr) 2006-08-03
EP1844045A1 (fr) 2007-10-17
AU2006208547B2 (en) 2011-02-10
ATE447572T1 (de) 2009-11-15
JP2008528526A (ja) 2008-07-31
BRPI0607241A2 (pt) 2009-08-25
IL184561A0 (en) 2007-10-31
KR100915472B1 (ko) 2009-09-03
AU2006208547A1 (en) 2006-08-03
TW200637859A (en) 2006-11-01
US7442710B2 (en) 2008-10-28
CN101146808B (zh) 2011-10-12
NO20073717L (no) 2007-08-23
CN101146808A (zh) 2008-03-19
EP1844045B1 (fr) 2009-11-04
ES2332529T3 (es) 2010-02-08
IL184561A (en) 2011-03-31
RU2007126951A (ru) 2009-03-10
JP4829900B2 (ja) 2011-12-07
WO2006079467A1 (fr) 2006-08-03
AR052662A1 (es) 2007-03-28
KR20070099030A (ko) 2007-10-08

Similar Documents

Publication Publication Date Title
IL184901A0 (en) 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
IL184557A (en) Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1
PL1891066T3 (pl) Związki i kompozycje jako inhibitory kinazy białkowej
EP1841431A4 (fr) Composes et compositions utilises en tant qu'inhibiteurs de proteines kinases
IL179613A0 (en) Compounds and compositions as protein kinase inhibitors
EP1713806A4 (fr) Composes et compositions tenant lieu d'inhibiteurs de la proteine kinase
IL182687A0 (en) Compounds and compositions as protein kinase inhibitors
IL192053A0 (en) 2-adamantylurea derivatives as selective 11??-hsd1 inhibitors
IL194404A0 (en) Benzyl phenyl glucopyranoside derivatives and pharmaceutical compositions containing the same
IL185199A0 (en) Indole compound and use thereof
IL196313A0 (en) Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumor agents
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
AP2007004198A0 (en) Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors
IL187620A0 (en) 17??-hsd1 and sts inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
IL225653A0 (en) Homo- and hetero-cyclic compounds suitable as cetp inhibitors
GB0512940D0 (en) Compounds and their use
ZA200706672B (en) 2,4-Diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors
EP1942108A4 (fr) Compose contenant un groupe basique et son utilisation
EP1765820A4 (fr) Composes et compositions utilises en tant qu'inhibiteurs des proteines kinases
ZA200703130B (en) Compounds and compositions as protein kinase inhibitors
GB0520743D0 (en) Compounds and their use
ZA200705898B (en) Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors
AP1963A (en) Substituted pyrrole derivatives and their use as HMG-co inhibitors
PL1840121T3 (pl) Pochodna glicyny i jej zastosowanie